RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD).  RetroSense is developing optogenetic approaches to partial vision restoration in retinitis pigmentosa and potentially dry age-related macular degeneration.

Read the entire article here.

Similar Posts